HIV :: FDA Accepts New Drug Application for Priority Review of Investigational HIV treatment TMC125
Tibotec Pharmaceuticals Ltd. announced that the New Drug Application (NDA) for TMC125 (etravirine), an investigational non-nucleoside reverse transcriptase inhibitor (NNRTI), has been accepted for priority review by the United States Food and Drug Administration (FDA).